4Sc AG is a leading biopharmaceutical company that is committed to pioneering innovative therapies for patients with severe diseases. The company's corporate philosophy revolves around the core values of dedication, collaboration, and excellence. By maintaining a patient-centric approach, 4Sc AG aims to develop breakthrough treatments with the potential to improve the lives of individuals worldwide. With a focus on scientific expertise and ethical practices, 4Sc AG consistently strives to optimize its research and development efforts, ultimately aiming to provide effective and safe therapies that address unmet medical needs.

4Sc AG is primarily present in Germany and Europe.

Some of the significant milestones achieved by 4Sc AG include the successful initiation of Phase II clinical trials for their lead product, resminostat, in several indications such as hepatocellular carcinoma and cutaneous T-cell lymphoma. The company has also formed strategic partnerships and collaborations to advance their pipeline, including a collaboration with immunotherapy-focused biotech, BioNTech. Additionally, 4Sc AG has received multiple grants and funding awards to support their research and development efforts. These achievements highlight 4Sc AG's commitment to advancing innovative therapies and their potential to deliver breakthrough treatments in the field of oncology.

4Sc AG is a German biopharmaceutical company focused on the development of innovative immunotherapies for cancer treatment. Established in 2007, 4Sc AG has rapidly grown and positioned itself as a pioneer in the field of personalized medicine. The company concentrates on developing targeted therapies that activate the patient's immune system to fight tumors effectively. With a strong emphasis on research and development, 4Sc AG has built a diverse pipeline of drug candidates aiming to address several cancer indications. The company's commitment to scientific excellence and patient-centric approach has garnered recognition within the medical and investment communities. 4Sc AG continues to strive towards providing groundbreaking solutions in the fight against cancer.

The main competitors of 4Sc AG in the market include pharmaceutical companies such as Roche Holding AG, Novartis AG, and Bristol-Myers Squibb Company.

4Sc AG is primarily active in the biotechnology industry.

4Sc AG, a renowned biotech company, operates on an innovative business model focusing on the research and development of targeted small molecule drugs. The company specializes in the discovery and advancement of novel therapies in the field of immune-oncology and autoimmune diseases. By leveraging its proprietary technology platforms, 4Sc AG aims to identify promising drug candidates and advance them through pre-clinical and clinical development phases. With a strong emphasis on precision medicine, 4Sc AG endeavors to develop tailored treatments that address the specific needs of patients. By combining cutting-edge science with a patient-centric approach, 4Sc AG is dedicated to revolutionizing the treatment landscape in various diseases and making a positive impact on patients' lives.

De 4Sc K/W is -6,82.

De 4Sc KUV is 0,97.

De AlleAktien Kwaliteitsscore voor 4Sc is 3/10.

De verwachte 4Sc omzet is 31,00 mln. EUR.

De verwachte 4Sc winst is -4,42 mln. EUR.

The 4Sc AG is a biopharmaceutical company specializing in the development of drugs for the treatment of cancer. The company is divided into two divisions: 4SC Discovery and 4SC Clinical Development. 4SC Discovery focuses on the research and development of new drugs, while 4SC Clinical Development is responsible for conducting clinical trials and obtaining market approval for the drugs. The company utilizes innovative technologies and methods, with a focus on epigenetics, to develop new drug candidates. Resminostat is a promising drug candidate being developed for the treatment of solid tumors and hematological malignancies. 4SC works closely with external partners, including academic institutions and pharmaceutical companies, to bring their drug candidates to market. The overall business model is focused on developing innovative drugs for cancer patients and expediting the development process through research, partnerships, and collaboration.

4Sc keert een dividend van 0 EUR uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor 4Sc of het bedrijf keert geen dividend uit.

De ISIN van 4Sc is DE000A14KL72.

Het WKN van 4Sc is A14KL7.

De ticker van 4Sc is VSC.DE.

Binnen de laatste 12 maanden betaalde 4Sc een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal 4Sc naar verwachting een dividend van 0 EUR betalen.

De dividendrendement van 4Sc is momenteel .

4Sc betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

4Sc betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 EUR verwacht. Dit komt overeen met een dividendrendement van 0 %.

4Sc wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van 4Sc van 12-9-2024 ter hoogte van 0 EUR te ontvangen, moest je het aandeel voor de ex-datum op 12-9-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 12-9-2024.

In het jaar 2023 heeft 4Sc 0 EUR aan dividenden uitgekeerd.

De dividenden van 4Sc worden in EUR uitgekeerd.